No headlines found.
Globe Newswire (Thu, 20-Feb 9:00 AM ET)
Globe Newswire (Thu, 13-Feb 4:30 PM ET)
Shattuck Labs Announces Poster Presentation at Upcoming 2025 Crohn's and Colitis Congress
Globe Newswire (Tue, 4-Feb 7:00 AM ET)
Shattuck Labs Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference
Globe Newswire (Mon, 6-Jan 4:59 PM ET)
Shattuck Labs Provides Corporate Update and Highlights Upcoming Key Milestones in 2025
Globe Newswire (Thu, 2-Jan 7:00 AM ET)
Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.
Shattuck Labs trades on the NASDAQ stock market under the symbol STTK.
As of March 5, 2025, STTK stock price climbed to $1.24 with 115,007 million shares trading.
STTK has a beta of 0.62, meaning it tends to be less sensitive to market movements. STTK has a correlation of 0.00 to the broad based SPY ETF.
STTK has a market cap of $59.18 million. This is considered a Micro Cap stock.
Last quarter Shattuck Labs reported $3 million in Revenue and -$.33 earnings per share. This beat revenue expectation by $2 million and exceeded earnings estimates by $.09.
In the last 3 years, STTK traded as high as $11.76 and as low as $.94.
The top ETF exchange traded funds that STTK belongs to (by Net Assets): VTI, IWM, VXF, IWO, VTWO.
STTK has underperformed the market in the last year with a return of -86.9%, while SPY returned +15.2%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in STTK shares. However, STTK has outperformed the market in the last 3 month and 2 week periods, returning -0.8% and -1.6%, while SPY returned -3.7% and -4.6%, respectively. This indicates STTK has been having a stronger performance recently.
STTK support price is $1.13 and resistance is $1.33 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that STTK shares will trade within this expected range on the day.